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C/EBPaHuman cytomegalovirus (HCMV) lytic DNA replication is initiated at the cis-acting oriLyt region and requires
six core replication proteins along with UL84 and IE2. Although UL84 is thought to be the replication initiator
protein, little is known about its interaction with oriLyt. We have now performed chromatin
immunoprecipitation assays (ChIP) using antibodies speciﬁc to UL84, IE2, UL44, CCAAT/enhancer binding
protein (C/EBPα) and PCR primers that span the entire oriLyt region to reveal an evaluation of speciﬁc
protein binding across oriLyt. UL84 interacted with several regions of oriLyt that contain C/EBPα
transcription factor binding sites. Mutation of either of one of C/EBPα (92,526 or 92,535) sites inactivated
oriLyt and resulted in the loss of binding of UL84. These data reveal the regions of interaction within oriLyt for
several key replication proteins and show that the interaction between UL84 and C/EBPα sites within oriLyt
is essential for lytic DNA replication.© 2009 Elsevier Inc. All rights reserved.Introduction
Human cytomegalovirus (HCMV) lytic replication is mediated by
the cis-acting element oriLyt (Anders et al., 1992a; Anders and
Punturieri, 1991; Hamzeh et al., 1990; Masse et al., 1992). OriLyt is
composed of a “core” domain located between nts 91,751 and 93,299
containing two essential regions (I and II) (Xu et al., 2004b; Zhu,
Huang, and Anders, 1998). Essential region II contains an RNA–DNA
hybrid structure that can form a stem–loop composed of an RNA
strand. This RNA stem–loop interacts with the virus-encoded protein
UL84 in vitro as well as in the infected cell environment and in
packaged virions (Colletti et al., 2007; Prichard et al., 1998). Part of
essential region I contains an IE2/UL84-responsive bidirectional
promoter suggesting that transcription plays a major role in oriLyt
activation (Xu et al., 2004b). Although a functional non-conventional
IE2 binding site was identiﬁed within in the oriLyt promoter region,
other cis-acting elements within oriLyt that participate in activation/
repression of initiation of lytic DNA synthesis are unknown. Essential
region I also contains several transcription factor binding sites as well
as a oligopyrimidine rich region referred to as the Y-BLOCK (Zhu,
Huang, and Anders, 1998).
HCMV UL84 is a multifunctional factor required for lytic DNA
replication and the production of infectious virus (Xu et al., 2004a).ri).
ll rights reserved.UL84 has the ability to activate as well as repress transcriptional
activation (Gebert et al., 1997a). In addition, UL84 can interact with
RNA and shuttle between the nucleus and the cytoplasm (Lischka
et al., 2006). Many of these activities and the presence of speciﬁc
protein sequence domains, point to UL84 as being a member of the
DExD/H box family of proteins (Colletti et al., 2005). UL84 is
associated with IE2 in infected cells (Spector and Tevethia, 1994)
and although the exact nature of this association is unknown, this
interaction apparently leads to a repression of transactivation of at
least one HCMV encoded gene in transient assays (Gebert et al.,
1997b). Additionally, an IE2/UL84 interaction serves to activate the
oriLyt promoter and the binding of the two proteins is essential for
oriLyt-dependent DNA replication (Xu et al., 2004b). Recently, UL84
was shown to interact with two other viral encoded factors: UL44, the
viral polymerase processivity factor and pp65, a tegument protein
(Gao, Colletti, and Pari, 2008).
Although UL84 is presumed to be the oriLyt initiation protein little
is known about the interaction of this protein with oriLyt. One study
predicted that UL84 is a dUTPase, however no experimental evidence
exists to show that the protein has this activity (Davison and Stow,
2005). In an effort to deﬁne the role of UL84 in lytic replication we
investigated the DNA binding proﬁle of UL84 and two other viral
encoded proteins, UL44 and IE2, within the lytic origin in an infected
cell environment and, in the case of UL84, in the packaged virion. In
this report we identify UL84, UL44 and IE2 interaction domains within
oriLyt using the chromatin immunoprecipitation assay (ChIP). We
show that UL84 interacts with DNA sequences in oriLyt that contain
Fig.1. Interaction of UL84, UL44, IE2 and C/EBPαwith oriLyt. (A) Schematic of HCMV genome showing the location of oriLyt and the positions of two essential regions, various restriction enzyme recognition sites, RNA/DNA hybrids, C/EBPα/β,
IE2-binding sites, oriLyt promoter region and the RNA stem–loop structure. Also shown are the relative locations of PCR primers used for ChIP assays for DNA isolated from infected cells and puriﬁed virions. (B) ChIP assays showing the
interaction of UL84, IE2, UL44 and C/EBPα with various regions of oriLyt. Infected cells were prepared as described and speciﬁc antibodies to UL84 (Virusys), IE2 (Vancouver Biotech), UL44 (Bill Britt) or C/EBPα (Santa Cruz) were used for
immunoprecipitations. PCR primers from regions 1 to 5 are shown above each ChIP assay gel. The lanes of each ChIP assay are as follows: 1, PCR product from input DNA; 2, PCR product from immunoprecipitations using speciﬁc antibodies
shown to the left of the ﬁgure; 3, PCR product from immunoprecipitations using an unrelated antibody that was the same isotype as the test antibody. Also shown is a PCR ampliﬁcation of the HCMV UL144 loci from samples
immunoprecipitated using the anti-UL84 antibody. Lanes: 1, PCR product from input DNA; 2, PCR product from immunoprecipitations using the anti-UL84 antibody; 3, PCR product from immunoprecipitations using an unrelated antibody that
was the same isotype as the test antibody. Solid line shows sequences gaps.
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Fig. 2. C/EBPα interacts with the proposed oriLyt C/EBPα-binding site sequence in
vitro. Nuclear extract was prepared from HEK293 cells transfected with a C/EBPα
expression plasmid. Three microliters of nuclear extract was incubated with ds
oligonucleotides in the presence or absence of a C/EBPα speciﬁc antibody. Lanes: 1,
control oligonucleotide; 2, control oligonucleotide plus nuclear extract from cells
transfected with a C/EBPα expression plasmid; 3, control oligonucleotide plus nuclear
extract from cells transfected with a C/EBPα expression plasmid plus a C/EBPα speciﬁc
antibody; 4, control oligonucleotide plus nuclear extract from cells transfected with a C/
EBPα expression plasmid plus 20×unlabeled control oligonucleotide; 5, control
oligonucleotide plus untrasfected nuclear extract; 6; oriLyt C/EBPα oligonucleotide;
7, oriLyt C/EBPα oligonucleotide plus nuclear extract from cells transfected with a C/
EBPα expression plasmid; 8, oriLyt C/EBPα oligonucleotide plus nuclear extract from
cells transfected with a C/EBPα expression plasmid plus a C/EBPα speciﬁc antibody; 9,
oriLyt C/EBPα oligonucleotide plus nuclear extract from cells transfectedwith a C/EBPα
expression plasmid plus 20×unlabeled control oligonucleotide; 10, oriLyt C/EBPα
oligonucleotide plus untrasfected nuclear extract.
18 D. Kagele et al. / Virology 392 (2009) 16–23several CCAAT/enhancer binding protein (C/EBPα) transcription
factor binding sites. A 3-nucleotide mutation introduced into the
C/EBPα consensus sequences within HCMV oriLyt resulted in the
inability of UL84 to interact with these sites in transfected cells and
the inactivation of oriLyt in the transient replication assay. It also
appears that UL84 interacts with these elements independent of
binding with C/EBPα in that co-immunoprecipitations failed to detect
a UL84–C/EBPα interaction in infected or cotransfected cells. These
results strongly suggest that UL84 interacts with speciﬁc transcription
factor binding sites within oriLyt and imparts an as yet unidentiﬁed
function that is essential for oriLyt ampliﬁcation.
Results
Interaction of UL84, IE2, UL44 and C/EBPα with oriLyt
Although we previously demonstrated that UL84 interacts with a
speciﬁc stem–loop structure within oriLyt, we wanted to identify
other regions of oriLyt that interact with UL84. Since UL84 was
shown to associate with UL44 and IE2 we were also interested in
regions of oriLyt that interacted with these proteins and if their
interaction with oriLyt overlapped with UL84 (Gao, Colletti, and Pari,
2008; Spector and Tevethia, 1994). Lastly, HCMV oriLyt contains
several C/EBP binding sites and we wanted to investigate if UL84
interacted with regions of oriLyt that contained these sites (Fig. 1A).
C/EBP binding sites as well as other transcription factor binding
sites are found in other herpesvirus lytic origins and were shown to
be substrates for viral replication proteins (Lieberman et al., 1990;
Wang et al., 2003a; Wang et al., 2003b). In order to identify regions
of interaction we employed the ChIP assay using primers that
spanned most of oriLyt (Fig. 1). We previously used the ChIP assay
to identify IE2 and UL84 binding sites within oriLyt in infected cells
and, for UL84, in packaged virions at speciﬁc region within oriLyt
(Colletti et al., 2007; Xu et al., 2004b). We were interested in
expanding those studies to include the entire oriLyt region. For our
ChIP assays we used a C/EBPα-speciﬁc antibody in addition to IE2,
UL44 and UL84 speciﬁc antibodies. By examining the binding
domains for all of these proteins we sought to assemble a picture
of oriLyt interaction domains for UL84 and its identiﬁed binding
partners. Additionally, we wanted to determine if C/EBPα interacted
with oriLyt in an effort to identify a possible connection between
this protein and UL84.
We used infected cells or puriﬁed virus (for UL84) for ChIP assays
as previously described (Colletti et al., 2007). Only UL84 immuno-
precipitations were done from puriﬁed virions. DNA fragments were
estimated within the 300–500 base pair (bp) range (data not
shown). Fig. 1A is a schematic of the HCMV genome showing the
location of oriLyt and the speciﬁc primers used to amplify regions of
the lytic origin (Fig. 1. regions: R1–R5). Also shown is the location of
three clusters of C/EBPα transcription factor binding sites and
several key elements within oriLyt including the location of 2
essential regions and RNA–DNA hybrid structures. The ChIP assay
revealed that UL84 interacts with various regions of oriLyt all of
which contain C/EBPα transcription factor binding sites (Fig. 1B, R1,
R3 and R5). UL84 protein was also found bound to DNA in puriﬁed
virus localizing to regions R1 and R5 as shown by positive PCR
products from these samples (Fig. 1B). Since UL84 is known to
interact with IE2, we also investigated the binding of IE2 to speciﬁc
regions of oriLyt using an IE2-speciﬁc antibody (G13-12E2, Vancou-
ver Biotech). IE2 interacted with oriLyt regions R3, R4 and R5. The
interaction of IE2 with R4 and R5 is located in a domain that contains
a previously reported IE2-responsive promoter (Xu et al., 2004b). We
also examined the binding of UL44 (polymerase accessory factor/
UL84 binding partner) to oriLyt. UL44 was shown to interact with
regions R1, R2 and R5 (Fig. 1B). Two of these regions R1 and R5 are
also substrates for UL84, suggesting that the interaction of UL44 withthese regions is part of an UL84–UL44 protein complex. Lastly we
investigated the interaction of C/EBPα with oriLyt. C/EBPα inter-
acted with oriLyt domains R1 and R5 (Fig. 1B). Interestingly, no PCR
signal was detected in domain R4 which contains a proposed C/EBPα
binding site (Fig. 1B). As controls for the ChIP assay we performed
immunoprecipitations with an isotype speciﬁc unrelated antibody.
We also used a PCR primer set complementary to a region outside of
oriLyt, the UL144 locus. All of these control reactions failed to yield a
detectable PCR product (Fig. 1B).
These results show speciﬁc protein binding to HCMV oriLyt. One
interesting ﬁnding is that UL84 interacts with regions of oriLyt that
contain C/EBPα transcription factor binding sites. These ﬁndings lead
us to further investigate the functional signiﬁcance of a possible
interaction of UL84 with C/EBPα sites within oriLyt.
Predicted oriLyt C/EBPα binding motifs interact with C/EBPα in vitro
Since the ChIP assay showed that C/EBPα interactedwith oriLyt, we
evaluated the identiﬁed regions of oriLyt for the presence of possible C/
EBPα binding motifs. We used the software program TRANSFAC to
identify the sequence 5′-CCAAAT-3′ as predicted to interact with C/
EBPα. In order to show this experimentally, we performed an EMSA
using a double stranded (ds) oligonucleotide containing the oriLyt
sequence 5′-TTGCCCAAATTTGGTAAAAATTTGC-3′ or a control ds oligo-
nucleotide, 5′-GATCTGCTGATTGGCCCAGAGCGGGAACCAATCAGCG-3′,
shown previously to interact with C/EBPα (Wu et al., 2003). Nuclear
extracts were prepared from HEK293 cells transfected with a C/EBPα
expressionplasmid and incubatedwith the oriLyt proposed and control
C/EBPα-containing oligonucleotides. Both the control ds oligonucleo-
tide sequence as well as the oriLyt C/EBPα sequence interacted with
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C/EBPα-speciﬁc antibody (Fig. 2, arrows show supershift). This
experiment indicated that the predicted oriLyt C/EBPα binding site
interactedwith C/EBPα and strongly suggested that this is the C/EBPα-
interacting motif within oriLyt identiﬁed in the ChIP assay.
Intact C/EBPα sites are essential for ampliﬁcation of oriLyt
As a ﬁrst step in identifying a possible role for C/EBPα sites in
oriLyt function and DNA replication we used the powerful transient
DNA replication assay to determine if C/EBPα binding sites contribute
to lytic DNA replication (Anders et al., 1992b). We generated several
plasmids that contained mutations in one or more of the C/EBPα sites
found within oriLyt. Fig. 2A shows the location and nucleotide
coordinates of three C/EBPα transcription factor binding sites that
were mutated within oriLyt. Site 1 is at nts 92,183, site 2 is located atFig. 3. Intact C/EBPα sites are required for ampliﬁcation of oriLyt. (A) Schematic of oriLyt seq
factor binding sites and the mutations made within the oriLyt sequence. (B) Southern blot o
containing plasmids plus the internal control plasmid pALTER–OriLyt. Cells were infected 24 h
with DpnI and EcoRI. Following agarose gel separation and transfer to a nylon membrane, an
show the identiﬁcation of each plasmid.92,527 and site 3 is located at nts 92,534 (Fig. 3A). Four plasmids were
generated: pOriLyt-S1 contains a mutation in C/EBPα binding site 1,
pOriLyt-S2 contains a mutation in C/EBPα binding site 2, pOriLyt-S3
contains amutation in C/EBP binding site 3 and pOriLyt-S2/3 contains
mutations in C/EBPα binding sites 2 and C/EBPα 3 (Fig. 3A). These
plasmids were transfected into HF cells that were subsequently
infected with HCMV. As an internal control for oriLyt ampliﬁcationwe
also transfected the plasmid pALTER–oriLyt. This plasmid contains wt
oriLyt, however the cloning vector is larger (pALTER) than the parent
vector for wt oriLyt or the mutated oriLyt plasmids (pGEM7zf). This
allowed for the detection of both mutated and wt oriLyt plasmids
in the same cells and transfection sample. The internal control
would also demonstrate that the replication assay in each case was
functioning properly.
Total cellular DNAwas harvested 5 days post infection and cleaved
with EcoRI and DpnI. DNA samples were resolved using a 0.8% agaroseuence from nucleotides 92,174 to 92,541 showing the positions of C/EBPα transcription
f a transient transfection replication assay. HF cells were transfected with various oriLyt
post transfection and total cell DNAwas harvested 5 days post transfection and cleaved
d the blot was hybridized to a 32P-labeled-pGEM probe. Arrows to the left of the ﬁgure
Fig. 5. Mutation of C/EBPα site 2/3 results in the loss of UL84 binding in transfected
cells. HF cells (1×107) were transfected by electroporationwith either wt OriLyt (10 μg)
or pOriLyt-2/3 (10 μg) and a UL84 (5 μg) expression plasmid. Two days post
transfection cells were prepared for ChIP assays using a UL84 speciﬁc antibody or, in
the case of the control ChIP an unrelated antibody of the same isotype as the UL84
antibody. Lanes: 1, PCR product input DNA from cells cotransfected with wt OriLyt
containing plasmid and a UL84 expression plasmid; 2, PCR product from a ChIP assay
from cells transfected with an OriLyt containing plasmid and a UL84 expression
plasmid; 3, PCR product from a ChIP assay from cells transfected with an OriLyt
containing plasmid and a UL84 expression plasmid using an isotype control antibody.
PCR reactions were performed using primers that ﬂanked the C/EBPαβ transcription
factor binding sites within oriLyt: forward 5′-ACTCGAGTCACCATCCCATAAT-3′ and
reverse 5′-TTTTCGTAGAACGTTTCGTTAGAAG-3′. The plasmid used in the transfection
experiments is shown at the left of the ﬁgure.
20 D. Kagele et al. / Virology 392 (2009) 16–23gel that was subsequently transferred to a nylon membrane (ZetaP-
robe, BioRad) and hybridized with a 32P-labeled pGEM7zf (−) probe
as described previously (Xu et al., 2004b). Replicated, DpnI-resistant,
oriLyt plasmid is shown by the arrows at the left of Fig. 3B. Mutation of
C/EBPα binding site 1 had no effect on the efﬁciency of oriLyt
ampliﬁcation (Fig. 3B). However, mutations in either C/EBPα binding
site 1 or 2 resulted in a complete eradication of oriLyt ampliﬁcation
(Fig. 3B). Ampliﬁcation of the oriLyt internal control plasmid pALTER–
oriLyt was unchanged and indicated that transfection efﬁciency and
the assay itself was adequate (Fig. 3B). These results showed that C/
EBPα binding sites 2 and 3 were essential for oriLyt replication and
coupled with the results from the ChIP assay suggested that UL84
interacted with these sites in the infected cell environment.
UL84 does not interact with C/EBPα
A recent proteomics study of cellular and viral factors interacting
with UL84 in infected cells did not reveal C/EBPα (or C/EBPβ) as a
binding partner of UL84 (Gao, Colletti, and Pari, 2008). In order to take
a more exhaustive investigation of this we infected HF cells with
HCMV and 5 days post infection protein lysates were prepared. Protein
lysates were used to immunoprecipitate C/EBPα using a speciﬁc
antibody followed by Western blot analysis of immunoprecipitated
protein for the presence of UL84. No speciﬁc protein band was
detected using an antibody to UL84 on Western blots (Fig. 4, lane 2,
WB: UL84). We also did the reverse immunoprecipitation where we
used a UL84-speciﬁc antibody and then analyzedWestern blots for the
presence of C/EBPα using a speciﬁc antibody. This reverse experiment
also showed that no C/EBPα was detected, indicating that these two
proteins do not interact in infected cells (Fig. 4, lane 4, WB: C/EBPα).
Due to the low abundance of C/EBPα in human ﬁbroblasts we could
not detect the protein in the lysate (Fig. 4, lanes 1, 3).
As a further test for the possible interaction of UL84 with C/
EBPα, we also cotransfected a UL84 expression plasmid along with a
C/EBPα expression plasmid and performed the same immunopre-
cipitations that were done in infected cells. Again we could notFig. 4. C/EBPα does not interact with UL84 in infected or transfected cells. HF cells were
infected with HCMV and protein lysates were prepared 5 days post infection. Proteins
were immunoprecipitated using either a UL84 or C/EBPα-speciﬁc antibody. Immuno-
precipitated protein was analyzed by Western blot using the same antibodies. Lanes: 1 ,
infected cell lysate, 2, infected cell protein lysate immunoprecipitated with anti-C/
EBPα; 3, infected cell protein lysate; 4, infected cell protein lysate immunoprecipitated
with anti-UL84; 5, UL84 and C/EBPα cotransfected cell protein lysate; 6, cotransfected
protein lysate immunoprecipitated with anti-UL84; 7, UL84 and C/EBPα cotransfected
cell protein lysate; 8, cotransfected protein lysate immunoprecipitated with anti-C/
EBPα. The speciﬁc antibodies used to react with the Western blot are shown to the left
of the ﬁgure.detect C/EBPα when immunoprecipitations were performed using
anti-UL84 antibody (Fig. 4, lane 6, WB: C/EBPα), likewise we could
not detect UL84 when immunoprecipitations were performed using
a C/EBPα-speciﬁc antibody (Fig. 4, lane 8, WB: UL84). Based on
these ﬁndings we conclude that UL84 does not directly or indirectly
interact with C/EBPα.
Mutation of oriLyt C/EBPα sites resulted in the loss of UL84 interaction
with oriLyt
Our ﬁndings strongly suggest that UL84 interacts with C/EBPα
transcription factor binding sites within oriLyt and UL84 binds
independent of an interaction with C/EBPα. In order to analyze
binding of UL84 to C/EBPα in a cellular environment we again
performed a ChIP assay using the C/EBPα mutated versions of oriLyt.
We cotransfected HF cells with a UL84 expression plasmid along either
the wt oriLyt containing plasmid or pOriLyt-S2/3. In this plasmid
based ChIP assay, the transfection of UL84 alone resulted in a positive
PCR signal when DNA samples were prepared from cells transfected
with wild-type oriLyt (Fig. 5, lane 1). This indicated that UL84
interacts with C/EBPα/β sites in the absence of any other viral
protein. However no PCR product was detected from samples
transfected with pOriLyt-S2/3, which has mutated C/EBPα sites
(Fig. 5, lane 2). No PCR product was detected in control lanes where
ChIP assays were performed using an isotype speciﬁc but unrelated
antibody (Fig. 5, lane 3). These experiments show that UL84 interacts
with the C/EBPα sites within oriLyt and suggests that UL84 mediates
oriLyt DNA synthesis through this interaction.
Discussion
Although it was shown previously that UL84 interacts with an RNA
stem–loop structure within oriLyt, we investigated if there were other
binding sites within the lytic origin. As part of this endeavor we also
explored the possible interactions of two other viral proteins that are
known to bindwith UL84, IE2 and UL44. Interestingly, UL84was found
to be in puriﬁed (packaged) virions bound to DNA in several loci as
well as in the previously reported region containing the RNA stem–
loop structure. In the case of protein binding to R3 of oriLyt, we found
UL84 interacting with this region in the infected cell environment but
not in puriﬁed virions. This apparent discrepancy could be due to the
binding of UL84 to actively replicating sites as well as interacting with
DNA or RNA within the virion. The ChIP analysis of the entire oriLyt
region revealed that IE2 interacts with regions of the lytic origin that
contain IE2 binding sites and the region that is adjacent to the RNA–
DNA hybrid. It was previously demonstrated that IE2 interacts with a
IE2–UL84 responsive promoter within oriLyt (Xu et al., 2004b). In this
21D. Kagele et al. / Virology 392 (2009) 16–23report we show that IE2 interacts with region 5 (R5), which is also
associated with UL84 and UL44 binding. UL44 also interacts with
oriLyt in several regions associated with IE2 and UL84. Interestingly,
UL44, IE2 and UL84 all interact with R5 of oriLyt. This is the region of
oriLyt just adjacent to the RNA stem–loop structure and the
association of these proteins with this domain suggests that this
area could be the point of initiation of DNA replication within oriLyt.
At the very least, the interaction of all of these replication-associated
proteins with this region suggests that R5 is a signiﬁcant active site for
protein binding within oriLyt.
One of the main ﬁndings of this report is that UL84 binds to C/
EBPα transcription factor binding sites within oriLyt. These two sites
located at 92,534 and 92,527, are approximately 300 nts upstream
from the RNA stem–loop within oriLyt. This region is within a
previously described promoter regionwithin oriLyt (Xu et al., 2004b).
The oriLyt promoter is essential for activity and its function is not very
well deﬁned. The C/EBPα binding sites are also just downstream of
the Y-BLOCK, another element known to contribute to oriLyt function
(Zhu, Huang, and Anders, 1998). This report deﬁnes the C/EBPαβ
sites as essential elements within this region. Interestingly, C/EBPα
did not interact with R4 which contains a consensus C/EBPα-binding
site. This site may not interact with C/EBPα for various reasons
including that it may not be accessible by the protein. Mutation of
either one of the oriLyt C/EBPα binding motifs that do interact with
UL84 or C/EBPα resulted in a complete inactivation of oriLyt in the
transient assay. Because of the close proximity of these two sites we
acknowledge the possibility that the region identiﬁed could in fact be
only one UL84 binding site. The transient replication assay is perfectly
suited to evaluate the effect of mutations within oriLyt and the impact
on DNA synthesis directly. Since the transient replication assay
focuses only on DNA synthesis, the ability of this powerful assay to
efﬁciently and quantitatively assess speciﬁc mutations has been
invaluable in the herpesvirus ﬁeld (Anders et al., 1992b; AuCoin et al.,
2004; Dykes et al., 1997; Huang, Zhu, and Anders, 1996; Schepers
et al., 1993; Sinigalia et al., 2008; Zhu, Huang, and Anders, 1998). The
next step is to generate HCMV BACmid clones that have mutations
within oriLyt, however the results presented here are the ﬁrst report
of UL84 interacting with speciﬁc elements within oriLyt. This
observation points to a novel mechanism of activation for HCMV
lytic replication that is dependent upon the recognition by UL84 of
these two cis-acting sites and possibly the RNA stem–loop structure.
Also as mentioned above, given the richness of novel structures and
protein binding within this region, R5, this suggests that the initiation
of DNA synthesis may occur in this area. This is the ﬁrst report to
show an interaction of UL84 with a transcription factor binding site
within oriLyt.
Our attempts to show direct binding of UL84 to C/EBPα motifs
using in vitro assays did not show any speciﬁc interaction, suggesting
that other, as yet unidentiﬁed, cellular factors could be facilitating the
interaction of UL84 with these elements. Although we have not
explored the possibilities in this report we acknowledge that UL84
could be interacting with oriLyt through other forms of C/EBPα or a
Jun-C/EBPα complex. Although the motifs we identiﬁed within oriLyt
are consensus C/EBPα binding motifs we acknowledge that other as
yet unidentiﬁed factors could be interacting with these sequences.
However, our data strongly suggests that these motifs are essential for
oriLyt ampliﬁcation and the interaction of UL84 with these sequences
is required in the cellular environment.
The initial ChIP assay on infected cell DNA did identify C/EBPα
binding to regions of oriLyt that also interactedwith UL84 (Fig. 1). This
result suggested that UL84 is interacting with C/EBPα and both
proteins are binding to DNA. However, our evidence did not conﬁrm
this hypothesis and suggests that UL84 interacts with C/EBPα binding
sites in oriLyt independent of a C/EBPα–UL84 protein–protein
interaction. This is based on the observations that a proteomic
analysis of UL84 binding partners failed to show an interactionwith C/EBPα (Gao, Colletti, and Pari, 2008) and we failed to immunopreci-
pitate C/EBPα when using speciﬁc UL84 antibodies in pull down
assays in transfected as well as infected cells. We were also unable to
immunoprecipitate UL84 when using a C/EBPα-speciﬁc antibody in
similar pull down assays.
Interaction of viral initiator proteins with transcription factor
binding sites is observed in other herpesvirus systems. For example,
Epstein–Barr Virus (EBV) lytic replication initiator protein Zta can
interact with AP-1 sites within oriLyt in the absence of AP-1 binding
(Lieberman et al., 1990). Zta is a transcriptional activator and appears
to activate lytic replication by a dual mechanism (Sarisky et al., 1996).
UL84 alone is not associated with any known transactivation function;
although in conjunction with IE2 can activate the oriLyt promoter.
UL84 could play a dual role where binding to RNA within the lytic
origin could facilitate DNA synthesis and interaction with transcrip-
tion factor binding sites triggers transcription that also modulates
initiation of DNA replication. Further analysis is needed to determine if
the interaction of UL84 with C/EBPα binding motifs results in
transcriptional activation.
Materials and methods
Cells and virus
Human ﬁbroblasts and HEK293 cells and virus (AD169) were
maintained as previous described (Colletti et al., 2007; Colletti et al.,
2005; Xu, Colletti, and Pari, 2002).
Co-immunoprecipitation
Immunoprecipitations were performed as previously described
(Colletti et al., 2004) with the following minor changes. HEK293FT
cells were plated to 70 to 90% conﬂuency in 100-mm dishes. Cells
were transfected with 10 μg of the appropriate plasmids by using
TransIT-LT (Mirius) per manufacturer's recommendations. At 48 h
posttransfection cells were washed twice with PBS (pH 7.4) and
lysed by using 1 ml of lysis buffer A by shaking for 30 min at room
temperature. Cells were scraped from the plate and passed through
a 22-gauge needle three times. Cellular debris was removed by
centrifugation at 1500×g for 10 min. Lysates were mixed incubated
overnight at 4 °C speciﬁc antibodies. Coimmunoprecipitations
were carried out by using a nonconjugated immunoprecipitation
system.
Nuclear extract preparation and EMSA
HEK 293FT cells were transfected (TransIT-LT, Mirius) with 5 μg of
the plasmid pUC-hC/EBPα (gift from Dr. Darlington, Baylor College of
Medicine) expressing full-length human C/EBPα (Harris et al., 2001).
Two days post transfection cells were harvested and nuclear extract
was prepared using Sigma Nxtract CellLYTIC NuCLEAR extraction kit
according to the manufacturer's protocol. 5 μL of the nuclear extract
was subjected to SDS-PAGE and Western blot analysis to verify
protein expression.
For electromobility shift assays, 3 μL of nuclear extract was added
to a 20 μl reaction mixture containing 1×binding buffer (10 mM
HEPES [pH 7.5], 50 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM
phenylmethylsulfonyl ﬂuoride, 1% Triton X-100, 5% glycerol) and
incubated with 1 μL of [32P]dCTP-labeled oligonucleotides and
incubated at 25 °C for 30 min. For supershift assays 4 μL of C/EBPα
polyclonal antibody (Active Motif catalog # 39306) was incubated
with the reaction mixture for an additional 30 min. Samples were
resolved through a 4.5% non-denaturing polyacrylamide gel using
running buffer (10 mM HEPES, 1 mM EDTA, 0.5 mM EGTA; pH 7.5)
at 25 °C. Gels were dried and shifted bands were detected using a
phosphoimager (GE).
Table 1
oriLyt ChIP assay regions.
Region Nucleotide
coordinates
Protein binding Primers
R1 91150–
91597
UL84 (v/c),
UL44, C/EBPα
F: AAAGATCCGAACTTTAAAATTGTGTGTTTTT
R:TGCTCACCGCCTCGCCGGCCACGGGGTTGA
R2 91317–
91627
UL44 F: ACGTCGTGTATACATAACGGTGCCCGGTGT R:
TGCTCACCGCCTCGCCGGCCACGGGGTTGA
R3 91627–
92228
UL84 (c),
IE2
F: CTTTTGTTGGTCACGTGACCATCAGCGCAGG
R: ACCGTATGTCCGGAATTCCACAGGATGACG
R4 92110–
92519
IE2 F: AAACTTAACGCCGCCGCTTCTCAC R:
TTTGCCCCCCCCGGTTCCGGAGG
R5 92497–
92830
UL84 (v/c),
UL44, IE2,
C/EBPα
F: CTCCGGAACCGGGGGGGGCAAATTTTTA R:
ACGGCGCACATCTAGTGGAATTTTACCG
v=bound in virion.
c=infected cells.
22 D. Kagele et al. / Virology 392 (2009) 16–23Chromatin immunoprecipitation assay (ChIP)
Infected cells were treated as described previously (Xu et al., 2004b).
Protein–DNA complexes were immunoprecipitated using antibodies
speciﬁc for UL44 (gift fromWilliamBritt), UL84 (Virusys), IE2 (Vancouver
Biotech) and C/EBPα (Santa Cruz). PCR primer sequences are as follows
(Table 1): R1: forward 5′-AAAGATCCGAACTTTAAAATTGTGTGTTTTT-3′
and reverse 5′-TGCTCACCGCCTCGCCGGCCACGGGGTTGA-3′; R2: forward
5′-CCTGCGCTGATGGTCACGTGACCAACAA-3′ reverse 5′-CGTCGTGT-
ATACATAACGGTGCCCGGTG-3′ R3: forward 5′-CCGTTAGGGTTC-
CACCGTCCTCGGTGTACG-3′ R4: forward 5′-CGTCATCCTGTGGAA-
TTCCGGACATACGGT-3′ and reverse 5′-TTTGCCCCCCCCGGTTCCGGAGG-
3′; R5: forward 5′-ACGGCGCACATCTAGTGGAATTTTACCG-3′ and reverse,
5′-CTCCGGAACCGGGGGGGGCAAATTTTTA-3′.
Site-directed mutagenesis
The C/EBPα/β sites within oriLyt were mutated using QuickChange II
(Stratagene) and primers: for pOriLyt-S1: forward 5′-CCTACGTCA-
CACTCGCGTGAGGTCACCCACTCCGGATATACG-3′ and reverse: 5′-CGTA-
TATCCGGAGTGGGTGACCTCACGCGAGTGTGACGTAGG-3′; for pOriLyt-S2:
forward: 5′-GGGCAAATTTTTAGGTAATTTGGGCAACCAT-3′and reverse: 5′-
ATGGTTGCCCAAATTACCTAAAAATTTGCCC-3′; for pOriLyt-S3: forward: 5′-
AATTTTTACCAAATCCAGGCAACCATGATTT-3′ and reverse 5′-AAAT-
CATGGTTGCCTGGATTTGGTAAAAATT-3′; for pOriLyt-S2/3: forward, 5′-
GGGCAAATTTTTAGGTAATCCAGGCAACCATGATTTCCAATGG-3′ and
reverse, 5′-CCATTGGAAATCATGGTTGCCTGGATTACCTAAAAATTTGCCC-3′.
Cotransfection replication assay
The cotransfection replication assay was performed using HCMV
replication proteins as described previously (Pari and Anders, 1993;
Xu et al., 2004b) with wt UL84 expression vector or plasmids pOriLyt-
S1, pOriLyt-S2, pOriLyt-S3 or pOriLyt-S2/3. Transfections also con-
tained pALTER–oriLyt which was generated by subcloning oriLyt into
the pALTER vector (Promega).
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